Quintiles Transnational Holdings Inc. (Q): Kevin K Gordon , EVP and COO of Quintiles Transnational Holdings Inc. sold 24,000 shares on Apr 12, 2016. The Insider selling transaction was reported by the company on Apr 14, 2016 to the Securities and Exchange Commission. The shares were sold at $69.90 per share for a total value of $1,666,508.00 according the SEC Form 4 Filing.
Company has been under the radar of several Street Analysts.Quintiles Transnational Holdings Inc is Downgraded by Sun Trust Rbsn Humphrey to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Mar 28, 2016.Quintiles Transnational Holdings Inc is Upgraded by Avondale to Mkt Perform. Earlier the firm had a rating of Mkt Underperform on the company shares. The Rating was issued on Feb 11, 2016.
Currently the company Insiders own 12.1% of Quintiles Transnational Holdings Inc shares according to the proxy statements.Institutional Investors own 88.56% of Quintiles Transnational Holdings Inc shares.
Shares of Quintiles Transnational Holdings Inc (Q) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.48 points or -0.68% at $70.35 with 12,82,891 shares getting traded. Post opening the session at $71.23, the shares hit an intraday low of $70.05 and an intraday high of $71.44 and the price vacillated in this range throughout the day. The company has a market cap of $8,399 M and the number of outstanding shares has been calculated to be 11,93,84,993 shares. The 52-week high of Quintiles Transnational Holdings Inc is $80.45 and the 52-week low is $55.011.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services including commercial services such as contract pharmaceutical sales forces and healthcare business services such as phase research market access and consulting and health information analytics and technology consulting.